If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
How to Dig Deep for Value in These Exuberant Markets
Value Investors Have to Go Deeper
Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments